What DHS did and why it matters
In a notice posted Wednesday, the Department of Homeland Security added BGI Group, its listed testing unit BGI Genomics Co., and spinoff MGI Tech Co. to the Uyghur Forced Labor Prevention Act Entity List. Being named triggers a default assumption that their products were made with forced labor, blocking entry into the US unless importers overturn that presumption.
DHS said the companies engaged with officials in China's Xinjiang region on genetic testing that enables "the monitoring, surveillance and repression of ethnic minorities by the government of the People's Republic of China, including the abhorrent practice of forced labor." The agency also cited a goal of shielding economic and corporate interests. Homeland Security Secretary Markwayne Mullin said, "This is about enforcing our laws, protecting American businesses from unfair competition, and making clear that companies connected to forced labor will not get a free pass in this country." The three were described collectively as "one of the largest advanced gene-sequencing and genetic-material collection enterprises in the world."
The bigger picture: rising biotech friction
The three firms were already restricted by other US blacklists that limit access to American tech and government contracts. Cutting off imports is the toughest step yet and lands as competition in life sciences intensifies between Washington and Beijing.
Beijing pushed back, urging the US to stop "attacks and smears" and pledging to take necessary steps to protect Chinese enterprises. "The U.S. measures have seriously undermined the legitimate rights and interests of the relevant Chinese enterprises and severely disrupted the stability of global industrial and supply chains," said Liu Chang, spokesperson for China's embassy in Washington. Following an earlier July tranche that targeted smaller companies, Beijing hit six U.S. entities with sanctions.
Last year, China also put Illumina Inc. on its unreliable entity list and barred its sequencing machines, saying it was retaliating against tariffs newly imposed at the direction of President Donald Trump. Beijing has denied Western allegations of genocide in Xinjiang.
Understanding how new developments reshape markets can help investors find smarter opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
What the companies say and their US exposure
BGI Group and MGI Tech rejected the allegations and said they adhere to internationally recognized principles on human rights and labor standards. BGI said it will "actively communicate with the relevant authorities and take appropriate measures as needed." MGI said it will "challenge the designation" and pursue removal from the list.
Both also emphasized that business tied to the US is a small slice of their operations. BGI Genomics has reported that the Americas accounted for under 2% of its 2025 revenue. MGI said about 8% of its revenue comes from the Americas and has warned that geopolitics are pressuring results. In February, MGI chose to divest its US unit, Complete Genomics, citing an "increasingly grim policy environment in the US market." Product-wise, MGI sells a lineup of gene sequencers to researchers, biotech companies, and hospitals, while BGI Genomics offers sequencing products and services alongside other diagnostic tests.
What could come next and the investor angle
Expect more tightening. Kit Conklin, Exiger's chief strategy and global affairs officer, said additional U.S. actions against Chinese biotech are probable, and could touch clinical trials, testing, and modeling; Exiger is a supply-chain AI company that assists with enforcing statutes such as the Forced Labor Prevention Act.
The entity roster stems from a 2021 law and now counts 190 names, and none have yet restarted shipments into the US by satisfying the law's proof standard. The bottom line: import bans may have limited near-term revenue impact on BGI Genomics and MGI given their Americas mix, but they raise the stakes for life-sciences supply chains and for any company exposed to cross-border genomics hardware, services, or data. Keep an eye on sequencing equipment vendors, clinical research networks, and hospital procurement that could shift as rules evolve.
Learning to use thoughtful tools can make investment decisions more confident and timely. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
